The results showed that the BTN/BTNL expression levels were diversified across cancers, among which the most typical high expression levels in tumors are kidney renal clear cell carcinoma (KIRC), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), skin cutaneous melanoma (SKCM), and stomach adenocarcinoma (STAD). This evidence concerns the gene BTN1A1 and diffuse large B-cell lymphoma.